On March 11, Gelonghui reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical") received the drug registration certificates approved and issued by the National Medical Products Administration for injectable Nicorandil in two specifications: 2mg and 12mg. Injectable Nicorandil is primarily used for unstable angina and acute heart failure, improving coronary microcirculation, effectively reducing cardiovascular events, and significantly reducing the risk of acute coronary syndrome, providing substantial benefits to clinical patients.
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
中恒集团(600252.SH):控股子公司获得药品注册证书
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary has obtained a Pharmaceutical registration certificate.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Like
Views 302
Write a comment
Statement
This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report